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Introduction
============

Accurate and rapid diagnostic tests will be critical for achieving control of coronavirus disease 2019 (covid-19), a pandemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnostic tests for covid-19 fall into two main categories: molecular tests that detect viral RNA, and serological tests that detect anti-SARS-CoV-2 immunoglobulins. Reverse transcriptase polymerase chain reaction (RT-PCR), a molecular test, is widely used as the reference standard for diagnosis of covid-19; however, limitations include potential false negative results,[@ref1] [@ref2] changes in diagnostic accuracy over the disease course,[@ref3] and precarious availability of test materials.[@ref4] Serological tests have generated substantial interest as an alternative or complement to RT-PCR in the diagnosis of acute infection, as some might be cheaper and easier to implement at the point of care. A clear advantage of these tests over RT-PCR is that they can identify individuals previously infected by SARS-CoV-2, even if they never underwent testing while acutely ill. As such, serological tests could be deployed as surveillance tools to better understand the epidemiology of SARS-CoV-2 and potentially inform individual risk of future disease.

Many serological tests for covid-19 have become available in a short period, including some marketed for use as rapid, point-of-care tests. The pace of development has, however, exceeded that of rigorous evaluation, and important uncertainty about test accuracy remains.[@ref5] We undertook a systematic review and meta-analysis to assess the diagnostic accuracy of serological tests for SARS-CoV-2 infection. Our objectives were to evaluate the quality of the available evidence, to compare pooled sensitivities and specificities of different test methods, and to identify study, test, and patient characteristics associated with test accuracy.

Methods
=======

Search strategy and selection criteria
--------------------------------------

Our systematic review and meta-analysis is reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines[@ref6] (see supplementary file). We searched Ovid-Medline for studies published in 2020, with no restrictions on language. Subject headings/subheadings (when applicable) combined with text words were used for the concepts of covid-19 (or SARS-CoV-2) and serological tests. The supplementary file provides the complete search strategy, run on 6 April 2020 and repeated on 30 April 2020. To identify pre-peer reviewed (preprints) studies, we searched the entire list of covid-19 preprints from medRxiv and bioRxiv (<https://connect.medrxiv.org/relate/content/181>) initially on 4 April 2020, and again on 28 April 2020. We also considered articles referred by colleagues or identified in references of included studies.

Eligible studies were randomised trials, cohort or case-control studies, and case series, reporting the sensitivity or specificity, or both of a serological test for covid-19. We excluded review articles, editorials, case reports, modelling or economic studies, articles with sample sizes less than five, and studies that only reported analytical sensitivity (ie, dilutional identification of detection limits).[@ref7] Three investigators (MB, GT, FAK) independently screened titles and abstracts, and two (MB, GT) independently screened full text papers. We used a sensitive screening strategy at the title or abstract level wherein selection by a single reviewer was sufficient for a study to undergo full text review. A third reviewer (FAK) resolved disagreements between reviewers at the full text stage. In the systematic review and meta-analyses, we included studies when sensitivity or specificity, or both of at least one covid-19 serological test was measured against a reference standard of viral culture or RT-PCR.

Data analysis
-------------

In our primary analysis, we estimated pooled sensitivity and specificity by method of serological test. We expected that accuracy would be associated with the immunoglobulin class being measured, as is the case for other coronaviruses.[@ref8] [@ref9] [@ref10] As such, we stratified the primary results by class of immunoglobulin detected.

One investigator (MB) extracted aggregate study level data using a piloted standardised electronic data entry form. For each study, a second reviewer (ZL or EM) verified all entered data. No duplicate data were identified. We collected information on study characteristics (location, design), study populations (age, sex, clinical severity, sources of populations used for estimating specificity), the timing of specimen collection in relation to onset of symptoms, and methodological details about index and reference tests. We categorised the tests by method: enzyme linked immunosorbent assays (ELISAs), lateral flow immunoassays (LFIAs), or chemiluminescent immunoassays (CLIAs). In several studies, investigators assessed the accuracy of more than one test method (eg, ELISA and LFIA) or more than one particular index test (eg, one study evaluated nine different LFIAs). For each particular index test performed in a study, we extracted the numbers needed to construct 2×2 contingency tables. Each evaluation of a particular index test was considered its own study arm. For example, a study that assessed nine LFIAs and two ELISAs on the same set of patients would contribute 11 study arms.

Two reviewers independently assessed risks of bias and applicability concerns using the quality assessment of diagnostic accuracy studies 2 (QUADAS-2) tool, for the domains of patient selection, performance of the index test, performance of the reference test, and flow and timing (for risk of bias only).[@ref11] Conflicts were resolved through consensus. We performed a quality assessment for each test method and population. For example, an article that assessed nine LFIAs and two ELISAs on the same set of patients would have two QUADAS-2 assessments (one for the LFIAs and one for the ELISAs).

The main summary measures were pooled sensitivity and pooled specificity, with 95% confidence intervals estimated using bivariate generalised linear mixed models. We specified random effects at the level of the particular study and of the particular test. The study level random effect accounted for correlation of results that could arise from study level factors, such as using the same set of samples to evaluate more than one test in a study. The test level random effect was added to account for differences arising from characteristics of individual tests. When models with two random effects did not converge, we used only the test level random effect.

We first estimated pooled sensitivity and specificity by test method (ELISA, LFIA, CLIA) and immunoglobulin class detected (IgM or IgG, or both). Separately, we reported results from studies evaluating serological tests that measured IgA or total immunoglobulin levels and without meta-analyses owing to small numbers. To describe heterogeneity, we constructed summary receiver operating characteristic (ROC) curves with 95% prediction regions, estimated using bivariate meta-analysis with a test level random effect only, and forest plots. As our models were bivariate, we did not use the I^2^ statistic. Studies that did not report both sensitivity and specificity were excluded from bivariate meta-analyses.

To assess prespecified variables as potential determinants of diagnostic accuracy, we compared pooled sensitivity and specificity across several subgroups according to: peer review status; reporting of data at the level of patients or samples; the type of SARS-CoV-2 antigen used; whether testing was by commercial kit or an in-house assay; whether the population used to estimate specificity consisted of samples collected before the emergence of SARS CoV-2, individuals without suspected covid-19 tested during the epidemic, individuals with suspected covid-19, or individuals with other viral infections; and the timing of sample collection in relation to the onset of symptoms (during the first week, during the second week, or after the second week). In these analyses, to maximize sample size we pooled data regardless of immunoglobulin class. To do so, we used the combined IgG and IgM result when available, otherwise we used the separate IgG and IgM results. For tests that had a 2×2 table for IgM and another 2×2 table for IgG, both contributed arms, sharing the same test level and study level random effects. Because data were not available to study the association between the timing of sampling and specificity, this analysis was done with univariate models and included studies that only reported sensitivity.

We used the statistical software R[@ref12] package Lme4[@ref13] for meta-analyses, and package mada to create summary ROC curves.[@ref14]

Patient and public involvement
------------------------------

Patients were not involved in the development of the research question or its outcome measures, conduct of the research, or preparation of the manuscript.

Results
=======

[Figure 1](#f1){ref-type="fig"} shows the selection of studies. Overall, 5014 records (4969 unique) were identified through database searches and two full text articles from hand searches. In total, 4696 records based on screening of titles or abstracts and 235 after full text review were excluded. Forty studies totalling 73 study arms[@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] met the inclusion criteria. [Table 1](#tbl1){ref-type="table"} summarises the studies by test method; the sum of the number of studies exceeds 40 because some evaluated more than one method. Seventy per cent (28/40) of the studies were from China,[@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35] [@ref38] [@ref39] [@ref40] [@ref41] [@ref45] [@ref46] [@ref47] [@ref48] 8% (3/40) from Italy,[@ref15] [@ref36] [@ref43] and the remainder from the United States (3/40),[@ref42] [@ref50] [@ref52] Denmark (1/40),[@ref51] Spain (1/40),[@ref37] Sweden (1/40),[@ref53] Japan (1/40),[@ref44] the United Kingdom (1/40),[@ref49] and Germany (1/40).[@ref54] Both sensitivity and specificity were reported in 80% (32/40) of the studies, sensitivity alone in 18% (7/40), and specificity alone in 3% (1/40).[@ref33] Among included studies, 50% (20/40) were not peer reviewed. Eighty per cent (32/40) of studies used a case-control design for selecting the study population and 10% (4/40) included outpatient populations. Disease severity was reported in 40% (16/40) and sensitivity stratified by time since symptom onset was reported in 45% (18/40). Several studies used samples rather than individual patients to estimate accuracy. In these studies, one patient could have contributed multiple samples for estimating sensitivity or specificity, or both. Approaches to estimating specificity included using specimens collected before the emergence of covid-19; specimens collected during the epidemic from individuals not suspected of having covid-19, or specimens from individuals with covid-19 symptoms and a negative RT-PCR result for SARS-CoV-2; or specimens from individuals with laboratory confirmed infection with other viruses (respiratory or non-respiratory). Supplementary tables S1 and S2 report the characteristics of each individual study.
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###### 

Summary of characteristics of included studies, stratified by method of serological testing

  Characteristics                                                                               ELISA          LFIA         CLIA      Other\*                  
  --------------------------------------------------------------------------------------------- ------- ------ ------ ----- ------ -- --------- ------ -- ---- -----
  Total                                                                                         15      2548          17†   1857      13        3750      3    140
  Peer reviewed:                                                                                                                                                
   Yes                                                                                          8       1339          7     859       7         3090      1    16
   No                                                                                           7       1209          11    1047      6         660       2    123
  Geographical location:                                                                                                                                        
   China                                                                                        11      1572          8     911       12        3635      1    57
   Denmark                                                                                      1       112           1     62        \-                  1    16
   Italy                                                                                        \-      \-            3     301       1         125       \-   \-
   Japan                                                                                        \-      \-            1     160       \-        \-        \-   \-
   Spain                                                                                        \-      \-            1     100       \-        \-        \-   \-
   Sweden                                                                                       \-      \-            1     153       \-        \-        \-   \-
   United Kingdom                                                                               1       90            1     90        \-        \-              
   United States                                                                                2       774           1     80        \-        \-        1    67
   Germany                                                                                      \-      \-            1     49        \-        \-        \-   \-
  Clinical setting:                                                                                                                                             
   Inpatient only                                                                               11      1307          9     1508      11        3119      1    16
   Outpatient                                                                                   \-      49            1     49        \-        \-        \-   \-
   Inpatient and outpatient                                                                     2       170           3     349                           \-   \-
   Not reported                                                                                 2       1041          5     778       2         631       2    124
  Study design:                                                                                                                                                 
   Case-control                                                                                 15      2548          12    894       11        3410      2    83
   Cohort                                                                                       0       \-            6     1012      1‡        56        1    57
  Time from symptom onset to index test§:                                                                                                                       
    First week                                                                                  6       172           7     190       5         41        \-   \-
   Second week                                                                                  7       239           9     195       5         105       \-   \-
   Third week or later                                                                          5       159           9     215       5         328       \-   \-
  Accuracy at level of patient or sample:                                                                                                                       
   Patient                                                                                      6       1495          10    1407      8         3080      2    73
   Samples††                                                                                    9       2115          8     1252      5         1599      1    132
  Population for estimating specificit*y*‡‡:                                                                                                                    
   None                                                                                         2       \-            3     \-        3         \-        1    \-
   Stratified                                                                                   12      \-            14              8         \-              
  Samples collected before covid-19 epidemic                                                    6       985           5     384       1         330       1    32
  Samples collected during covid-19 epidemic in individuals not suspected of having covid-19¶   6       890           3     280       4         2296      \-   \-
  Individuals with suspected covid-19 but RT-PCR negative result                                \-      \-            6     378       4         167       1    33
  Individuals with confirmed other viral infection\*\*                                          3       259           1     52        1         167       \-   \-
  Mix of above                                                                                  1       519           1     32        2         144       \-   \-

ELISA=enzyme linked immunosorbent assay; LFIA=lateral flow immunoassay; CLIA=chemiluminescent immunoassay; RT-PCR=reverse transcriptase polymerase chain reaction.

Includes enzyme immunoassay, fluorescence immunochromatographic assay, liquid phase immunoassay.

Cassaniti et al[@ref15] includes two distinct populations, patients who were triaged or admitted to hospital, with different study design (cohort and case-control). This study as two different cohorts, hence sum of number of studies across LFIA rows is 18.

One study was poorly reported, and it was difficult to classify study design.

First week range: 0-7 days (one cohort with 0-10 days is counted in this group); second week: 7-14 days; third week: 15 days or more.

Patients could have contributed more than one sample, and analyses did not account for correlation.

Numbers include samples and patients. Some studies reported more than one type of population to access specificity.

Includes studies where timing was unclear.

Includes some samples originating from before the covid-19 epidemic, and some during the epidemic, as further stratification was not possible.

[Table 2](#tbl2){ref-type="table"} provides information about the serological (index) and reference tests that were used in the included studies. Supplementary table S3 provides details for each study. Most of the studies evaluated commercial serology test kits (see supplementary table S4 for names). Studies varied for measured immunoglobulin class and antigen target. Among 17 studies that evaluated potential point-of-care tests (LFIAs), only two performed testing at the point of care. Direct testing on whole blood specimens---as would be done at the point of care---was performed in 6/17 (35%) studies of LFIAs, and outcomes of such testing were available for 44 patients across all study arms (2% of LFIAs performed). All 39 studies that reported sensitivity used RT-PCR as the reference standard to rule in SARS-CoV-2 infection, but the type and number of specimens varied.

###### 

Characteristics of serological (index) and reference tests in included studies (n=40)

  Characteristics\*                                          No (%)
  ---------------------------------------------------------- ---------
  Commercial serological kit as index test:                   
   Yes                                                       23 (58)
   No                                                        16 (40)
   Unclear                                                   1 (3)
  Class of immunoglobulin measured by index test:             
   IgM                                                       24 (60)
   IgG                                                       25 (63)
   IgM and IgG                                               17 (43)
   IgA                                                       3 (8)
   Total Ig                                                  4 (10)
  Antigen target of immunoglobulin measured by index test:    
   Surface protein                                           11 (28)
   Nucleocapsid protein                                      8 (20)
   Surface and nucleocapsid proteins                         14 (35)
   Not reported                                              11 (28)
  Type of specimen for RT-PCR reference test†:                
   Nasopharyngeal                                            16 (40)
   Sputum, saliva, or oral, throat, or pharyngeal            8 (8)
   Not reported                                              15 (38)
  No of specimens for RT-PCR reference test†:                 
   2                                                         6 (15)
   1 or not reported                                         33 (85)

RT-PCR=reverse transcriptase polymerase chain reaction.

See supplementary table S3 for additional test characteristics of each study. Supplementary table S4 lists the commercial kits.

Denominator is 39 studies reporting sensitivity.

[Figure 2](#f2){ref-type="fig"} summarises the QUADAS-2 assessment, and supplementary figure S1 displays each of the 49 individual QUADAS-2 evaluations. For the patient selection domain, a high or unclear risk of bias was seen in 98% (48/49) of QUADAS-2 assessments, mostly related to a case-control design and not using consecutive or random sampling. For the index test domain, 73% (36/49) of assessments concluded a high or unclear risk of bias because it was not clear whether the serological test was interpreted blind to the reference standard or whether the cut-off values for classifying results as positive, negative, or indeterminate were prespecified. For LFIAs (18 of the QUADAS-2 assessments), when test results are subjectively interpreted by a human reader (eg, appearance of a line), a description of the number of readers and assessment of reliability were provided in 17% (3/18) of assessments. For the reference standard domain, we judged the risk of bias as unclear in 94% (46/49) of assessments owing to inadequate details about specimens used for RT-PCR or use of specimens other than nasopharyngeal swabs. We also classified the risk as unclear if fewer than two RT-PCRs were used to rule out infection, or if the number was not reported. Risk of bias from flow and timing was high or unclear in 67% (33/49) owing to missing information or results not stratified by the timing of sample collection in relation to symptom onset. Major applicability concerns for the index test were seen in 29% (14/49) of assessments, mostly owing to LFIA being performed in laboratories and not using point-of-care type specimens.
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[Table 3](#tbl3){ref-type="table"} enumerates within study and pooled sensitivity stratified by test type and immunoglobulin class. Within each test method (CLIA, ELISA, LFIA), point estimates were similar between the different types of immunoglobulins, and confidence intervals overlapped. Within each class of immunoglobulin, sensitivity was lowest for the LFIA method. [Table 4](#tbl4){ref-type="table"} reports on specificity. Pooled specificities ranged from 96.6% (95% confidence interval 94.3% to 98.2%) for LFIAs measuring IgM and IgG, to 99.7% (99.0% to 100%) for ELISAs measuring IgM. Pooled specificity for CLIA tests that measured IgM and IgG (n=2) could not be estimated because of non-convergence. For all test methods and immunoglobulin classes, visual inspection of summary ROC curves (supplementary figure S2) and of forest plots (supplementary figure S3) showed important heterogeneity.

###### 

Individual and pooled sensitivity by serological test method and immunoglobulin class detected\*

  Method and studies          IgM          IgG                      IgG or IgM                                               
  --------------------------- ------ ----- --------------------- -- ------------ ----- --------------------- -- ------ ----- ---------------------
  **ELISA (n=13 arms)**                                                                                                      
  Liu[@ref18]                 174    40    81.3 (75.6 to 86.0)      172          42    80.4 (74.5 to 85.1)      186    28    86.9 (81.7 to 90.8)
  Adams[@ref49]               28     12    70.0 (54.6 to 81.9)      34           6     85.0 (70.9 to 92.9)      34     6     85.0 (70.9 to 92.9)
  Whitman[@ref52]:                                                                                                            
   Commercial kit             74     56    56.9 (48.3 to 65.1)      96           34    73.8 (65.7 to 80.6)      98     32    75.4 (67.3 to 82.0)
   In-house                   \-     \-    \-                       \-           \-    \-                       94     36    72.3 (64.1 to 79.3)
  Liu[@ref28]                 \-     \-    \-                       \-           \-    \-                       127    26    83.0 (76.3 to 88.1)
  Freeman[@ref42]             \-     \-    \-                       \-           \-    \-                       95     4     96.0 (90.0 to 98.4)
  Zhao[@ref20]                143    30    82.7 (76.3 to 87.6)      112          61    64.7 (57.4 to 71.5)                    
  Lou[@ref30]                 74     6     92.5 (84.6 to 96.5)      71           9     88.8 (80.0 to 94.0)      \-     \-    \-
  Zhong[@ref38]               46     1     97.9 (88.9 to 99.6)      46           1     97.9 (88.9 to 99.6)      \-     \-    \-
  Xiang[@ref41]               51     15    77.3 (65.8 to 85.7)      55           11    83.3 (72.6 to 90.4)      \-     \-    \-
  Perera[@ref48]              37     10    78.7 (65.8 to 88.0)      34           13    72.3 (58.2 to 83.1)      \-     \-    \-
  Guo[@ref17]                 62     20    75.6 (65.3 to 83.6)      \-           \-    \-                       \-     \-    \-
  Lassauniere[@ref51]         \-     \-    \-                       20           10    66.7 (48.8 to 80.6)      \-     \-    \-
  Pooled                      689    190   81.1 (71.8 to 88.5)      640          187   80.6 (71.9 to 87.9)      634    132   84.3 (75.6 to 90.9)
  **LFIA (n=36 arms)**                                                                                                       
  Li[@ref23]                  328    69    82.6 (78.6 to 86.0)      280          117   70.5 (65.9 to 74.8)      352    45    88.7 (85.2 to 91.4)
  Garcia[@ref37]              12     43    21.8 (12.9 to 34.4)      23           32    41.8 (29.7 to 55.0)      26     29    47.3 (34.7 to 60.2)
  Imai[@ref44]                60     79    43.2 (35.2 to 51.5)      20           119   14.4 (9.5 to 21.2)       60     79    43.2 (35.2 to 51.5)
  Whitman[@ref52]:                                                                                                            
   Commercial kit 1           79     49    61.7 (53.1 to 69.7)      71           57    55.5 (46.8 to 63.8)      83     45    64.8 (56.1 to 72.6)
   Commercial kit 2           91     37    71.1 (62.7 to 78.2)      80           48    62.5 (53.0 to 70.4)      95     33    74.2 (66.0 to 81.0)
   Commercial kit 3           85     41    67.5 (58.9 to 75.0)      84           42    66.7 (58.1 to 74.3)      85     41    67.5 (58.9 to 75.0)
   Commercial kit 4           94     36    72.3 (64.1 to 79.3)      62           54    53.4 (44.4 to 62.3)      95     35    73.1 (64.9 to 80.0)
   Commercial kit 5           33     82    28.7 (21.2 to 37.5)      72           44    62.1 (53.0 to 70.4)      66     50    56.9 (47.8 to 65.5)
   Commercial kit 6           89     40    69.0 (60.6 to 76.3)      69           60    53.5 (44.9 to 61.9)      91     38    70.5 (62.2 to 77.7)
   Commercial kit 7           62     67    48.1 (39.6 to 56.6)      73           56    56.6 (48.0 to 64.8)      74     55    56.9 (47.8 to 65.5)
   Commercial kit 8           79     51    60.8 (52.2 to 68.7)      73           57    56.5 (47.6 to 64.4)      80     50    61.5 (53.0 to 69.0)
   Commercial kit 9           79     42    65.3 (56.5 to 73.2)      77           44    63.6 (54.8 to 71.7)      79     42    65.3 (56.5 to 73.2)
   Commercial kit 10          \-     \-    \-                       \-           \-    \-                       87     39    69.0 (60.5 to 76.5)
  Liu[@ref29]                 34     56    37.8 (28.5 to 48.1)      75           15    83.3 (74.3 to 89.6)      77     13    85.6 (76.8 to 91.4)
  Cassaniti[@ref15]:                                                                                                          
   Hospital admission group   25     5     83.3 (66.4 to 92.7)      24           6     80.0 (62.7 to90.5)       25     5     83.3 (66.4 to 92.7)
   Triage group               \-     \-    \-                       \-           \-    \-                       7      31    18.4 (9.2 to 33.4)
  Lou[@ref30]                 71     9     88.8 (80.0 to 94.0)      69           11    86.2 (77.0 to 92.1)                    
  Hoffman[@ref53]             20     9     69.0 (50.8 to 82.7)      27           2     93.1 (78.0 to 98.1)                    
  Chen[@ref35]                \-                                    7            0     100 (64.6 to 100)                      
  Zhang[@ref32]               \-     \-    \-                       \-           \-    \-                       106    16    86.9 (79.8 to 91.4)
  Paradiso[@ref43]            \-     \-    \-                       \-           \-    \-                       21     49    30.7 (20.5 to 41.5)
  Adams[@ref49]:                                                                                                              
   Commercial kit 1           \-     \-    \-                       \-           \-    \-                       18     15    54.5 (38.0 to 70.2)
   Commercial kit 2           \-     \-    \-                       \-           \-    \-                       23     15    60.5 (44.7 to 74.4)
   Commercial kit 3           \-     \-    \-                       \-           \-    \-                       21     12    63.6 (46.6 to 77.8)
   Commercial kit 4           \-     \-    \-                       \-           \-    \-                       25     12    67.6 (51.5 to 80.4)
   Commercial kit 5           \-     \-    \-                       \-           \-    \-                       19     12    61.3 (43.8 to 76.3)
   Commercial kit 6           \-     \-    \-                       \-           \-    \-                       20     11    64.5 (46.9 to 78.9)
   Commercial kit 7           \-     \-    \-                       \-           \-    \-                       23     10    69.7 (52.7 to 82.6)
   Commercial kit 8           \-     \-    \-                       \-           \-    \-                       18     14    56.2 (39.3 to 71.8)
   Commercial kit 9           \-     \-    \-                       \-           \-    \-                       22     18    55.0 (39.8 to 69.3)
  Lassauniere[@ref51]:                                                                                                        
   Commercial kit 1           \-     \-    \-                       \-           \-    \-                       27     3     90.0 (74.4 to 96.5)
   Commercial kit 2           \-     \-    \-                       \-           \-    \-                       27     3     90.0 (74.4 to 96.5)
   Commercial kit 3           \-     \-    \-                       \-           \-    \-                       28     2     93.3 (78.7 to 98.2)
   Commercial kit 4           \-     \-    \-                       \-           \-    \-                       25     5     83.3 (66.4 to 92.7)
   Commercial kit 5           \-     \-    \-                       \-           \-    \-                       4      1     80.0 (37.6 to 96.4)
   Commercial kit 6           \-     \-    \-                       \-           \-    \-                       1      0     100 (20.7 to 100)
  Dohla[@ref54]               \-     \-    \-                       \-           \-    \-                       8      14    36.4 (19.7 to 57.0)
  Pooled                      1241   715   61.8 (50.8 to 71.8)      1186         764   64.9 (53.8 to 75.4)      1818   842   66.0 (49.3 to 79.3)
  **CLIA (n=10 arms)**                                                                                                       
  Lin[@ref27]                 65     14    82.3 (72.4 to 89.1)      65           14    82.3 (72.4 to 89.1)      72     7     91.1 (82.8 to 95.6)
  Ma[@ref47]                  209    7     96.8 (93.5 to 98.4)      209          7     96.8 (93.5 to 98.4)      215    1     99.5 (97.4 to 100)
  Cai[@ref24]                 158    118   57.2 (51.3 to 62.9)      197          79    71.4 (65.8 to 76.4)      \-     \-    \-
  Infantino[@ref36]           44     17    72.1 (59.8 to 81.8)      46           15    75.4 (63.3 to 84.5)      \-     \-    \-
  Zhong[@ref38]               46     1     97.9 (88.9 to 99.6)      45           2     95.7 (85.8 to 98.8)      \-     \-    \-
  Jin[@ref39]                 13     14    48.1 (30.7 to 66.0)      24           3     88.9 (71.9 to 96.1)      \-     \-    \-
  Xie[@ref40]                 15     1     93.8 (71.7 to 98.9)      16           0     100 (80.6 to 100)        \-     \-    \-
  Yangchun[@ref45]            144    61    70.2 (63.7 to 76.1)      197          8     96.1 (92.5 to 97.9)      \-     \-    \-
  Qian[@ref46]                432    71    85.9 (82.6 to 88.7)      486          17    96.6 (93.5 to 98.4)      \-     \-    \-
  Lou[@ref30]                 69     11    86.2 (77.0 to 92.1)      \-           \-    \-                       \-     \-    \-
  Pooled                      1195   315   84.3 (70.7 to 93.0)      1285         145   93.5 (84.9 to 98.1)      287    8     97.8 (46.2 to 100)

Ig=immunoglobulin; TP=true positive; FN=false negative; TN=true negative; FP=false positive; ELISA=enzyme linked immunosorbent assay; LFIA=lateral flow immunoassay; CLIA=chemiluminescent immunoassay.

Pooled estimates were calculated using bivariate random effects meta-analysis; as such, they depart from what would be estimated by simple division of numerator by denominator. Supplementary table S4 lists the names of commercial assays.

###### 

Individual and pooled specificity by serological test method and immunoglobulin class detected\*

  Method and studies         IgM          IgG                      IgG or IgM                                              
  -------------------------- ------ ----- --------------------- -- ------------ ---- --------------------- -- ------ ----- ---------------------
  **ELISA (n=13 arms)**                                                                                                    
  Liu[@ref18]                100    0     100 (96.3 to 100)        100          0    100 (96.3 to 100)        100    0     100 (96.3 to 100)
  Adams[@ref49]              50     0     100 (93.0 to 100)        50           0    100 (92.9 to 100)        50     0     100 (92.8 to 100)
  Whitman[@ref52]:                                                                                                          
   Commercial kit            155    5     96.9 (92.9 to 100)       142          18   88.8 (82.9 to 92.8)      140    20    87.5 (81.5 to 91.8)
   In-house                  \-     \-    \-                       \-           \-   \-                       152    8     95.0 (90.4 to 97.4)
  Liu[@ref28]                \-     \-    \-                       \-           \-   \-                       116    4     96.6 (90.1 to 98.4)
  Freeman[@ref42]            \-     \-    \-                       \-           \-   \-                       515    4     99.2 (98.0 to 99.7)
  Zhao[@ref20]               210    3     98.6 (95.9 to 100)       195          2    99.0 (96.4 to 99.7)      \-     \-    \-
  Lou[@ref30]                300    0     100 (98.7 to 100)        100          0    100 (96.3 to 100)        \-     \-    \-
  Zhong[@ref38]              299    1     99.7 (98.1 to 100)       299          1    99.7 (98.1 to 100)       \-     \-    \-
  Xiang[@ref41]              60     0     100 (94.0 to 100)        57           3    95.0 (86.3 to 98.3)      \-     \-    \-
  Perera[@ref48]             207    0     100 (98.7 to 100)        204          3    98.6 (95.8 to 100%       \-     \-    \-
  Guo[@ref17]                285    0     100 (99.0 to 100)        \-           \-   \-                       \-     \-    \-
  Lassauniere[@ref51]        \-     \-    \-                       79           3    96.3 (89.8 to 98.7)      \-     \-    \-
  Pooled                     1666   9     99.7 (99.0 to 100)       1226         30   98.9 (96.7 to 99.8)      1073   36    97.6 (93.2 to 99.4)
  **LFIA (n=36 arms)**                                                                                                     
  Li[@ref23]                 117    11    91.4 (85.3 to 95.1)      177          11   94.1 (89.8 to 96.7)      116    12    90.6 (84.3 to 94.6)
  Garcia[@ref37]             45     0     100 (92.1 to 100)        45           0    100 (92.1 to 100)        45     0     100 (92.1 to 100)
  Imai[@ref44]               47     1     97.9 (89.1 to 100)       48           0    100 (92.6 to 100)        47     1     97.9 (89.1 to100)
  Whitman[@ref52]:                                                                                                          
   Commercial kit 1          138    21    86.8 (80.7 to 91.2)      151          8    95.0 (90.4 to 97.4)      134    25    84.3 (77.8 to 89.1)
   Commercial kit 2          141    8     94.6 (89.8 to 97.3)      141          8    95.0 (90.4 to 96.7)      136    13    91.3 (85.6 to 94.8)
   Commercial kit 3          144    15    90.6 (85.0 to 94.2)      148          11   93.1 (88.0 to 96.1)      142    17    89.3 (83.5 to 93.2)
   Commercial kit 4          129    31    80.6 (73.8 to 86.0)      152          6    96.2 (92.0 to 98.2)      129    31    80.6 (73.8 to86.0)
   Commercial kit 5          130    6     95.6 (90.7 to 98.0)      134          2    98.5 (94.8 to 99.6)      129    7     94.9 (89.8 to 97.5)
   Commercial kit 6          157    3     98.1 (94.6 to 99.4)      158          2    98.8 (95.6 to 100)       155    5     96.9 (92.9 to 98.7)
   Commercial kit 7          160    0     100 (97.7 to 100)        160          0    100 (97.7 to 100)        160    0     100 (97.7 to 100)
   Commercial kit 8          154    5     96.9 (92.9 to 98.6)      155          4    97.5 (93.7 to 99.0)      154    5     96.9 (92.9 to 98.7)
   Commercial kit 9          139    9     93.9 (88.8 to 96.8)      143          5    96.7 (95.6 to 99.9)      139    9     93.9 (88.8 to 96.8)
   Commercial kit 10         \-     \-    \-                       \-           \-   \-                       146    1     99.3 (96.2 to 100)
  Liu[@ref29]                83     6     93.3 (86.1 to 96.9)      82           7    92.1 (84.6 to 96.1)      81     8     91.0 (83.3 to 95.4)
  Cassaniti[@ref15]                                                                                                         
  Hospital admission group   30     0     100 (88.6 to 100)        30           0    100 (88.6 to100)         30     0     100 (88.6 to 100)
  Triage group               \-     \-    \-                       \-           \-   \-                       11     1     91.7 (64.6 to 98.5)
  Lou[@ref30]                205    4     98.1 (95.2 to 99.3)      208          1    99.5 (97.3 to 100)       \-     \-    \-
  Hoffman[@ref53]            124    0     100 (97.0 to 100)        123          1    99.2 (95.6 to 100)                     
  Chen[@ref35]               \-     \-                             11           1    91.7 (64.6 to 98.5)                    
  Zhang[@ref32]              \-     \-    \-                       \-           \-   \-                       41     0     100 (91.4 to 100)
  Paradiso[@ref43]           \-     \-    \-                       \-           \-   \-                       107    13    89.2 (82.3 to 93.6)
  Adams[@ref49]:                                                                                                            
   Commercial kit 1                                                                                           60     0     100 (94.0 to 100)
   Commercial kit 2          \-     \-    \-                       \-           \-   \-                       90     1     98.9 (94.0 to 100)
   Commercial kit 3          \-     \-    \-                       \-           \-   \-                       58     2     96.7 (89.6 to 99.1)
   Commercial kit 4          \-     \-    \-                       \-           \-   \-                       59     2     96.7 (89.6 to99.1)
   Commercial kit 5          \-     \-    \-                       \-           \-   \-                       58     2     96.7 (89.6 to 99.1)
   Commercial kit 6          \-     \-    \-                       \-           \-   \-                       59     1     98.3 (91.1 to 100)
   Commercial kit 7          \-     \-    \-                       \-           \-   \-                       57     3     95.0 (86.3 to 98.0)
   Commercial kit 8          \-     \-    \-                       \-           \-   \-                       60     0     100 (94.0 to 100)
   Commercial kit 9          \-     \-    \-                       \-           \-   \-                       138    4     97.2 (93.0 to 98.9)
  Lassauniere[@ref51]:                                                                                                      
   Commercial kit 1          \-     \-    \-                       \-           \-   \-                       32     0     100 (89.3 to 100)
   Commercial kit 2          \-     \-    \-                       \-           \-   \-                       32     0     100 (89.3 to 100)
   Commercial kit 3          \-     \-    \-                       \-           \-   \-                       32     0     100 (89.3 to 100)
   Commercial kit 4          \-     \-    \-                       \-           \-   \-                       17     0     100 (81.6 to 100)
   Commercial kit 5          \-     \-    \-                       \-           \-   \-                       12     3     80 (54.8 to 93.0)
   Commercial kit 6          \-     \-    \-                       \-           \-   \-                       13     2     86.7 (62.1 to 96.3)
  Dohla[@ref54]              \-     \-    \-                       \-                \-                       24     3     88.9 (71.9 to 96.1)
  Pooled                     1943   120   96.6 (93.8 to 98.4)      2055         66   97.6 (96.2 to 98.8)      2703   171   96.6 (94.3 to 98.2)
  **CLIA (n=10 arms)**                                                                                                     
  Lin[@ref27]                65     15    81.2 (71.3 to 88.3)      78           2    97.5 (91.3 to 99.3)      64     16    80.0 (70.0 to 87.3)
  Ma[@ref47]                 446    37    92.3 (89.6 to 94.4)      482          1    99.8 (98.8 to 100)       483    0     100 (99.2 to 100)
  Cai[@ref24]                167    0     100 (97.8 to100)         167          0    100 (97.8 to 100)        \-     \-    \-
  Infantino[@ref36]          60     4     93.8 (85.0 to 97.5)      64           0    100 (94.3 to 100)        \-     \-    \-
  Zhong[@ref38]              286    14    95.3 (92.3 to 97.2)      290          10   96.7 (94.0 to 98.2)      \-     \-    \-
  Jin[@ref39]                33     0     100 (89.4 to 100)        30           3    90.9 (76.4 to 96.9)      \-     \-    \-
  Xie[@ref40]                6      34    15.0 (7.1 to 29.1)       0            40   0.0 (0.0 to 8.8)         \-     \-    \-
  Yangchun[@ref45]           76     3     96.2 (89.4 to 98.7)      73           6    92.4 (84.4 to 96)        \-     \-    \-
  Qian[@ref46]               1529   29    98.1 (97.3 to 98.7)      1528         30   98.1 (97.3 to 98.6)      \-     \-    \-
  Lou[@ref30]                298    2     99.3 (97.6 to100)        \-           \-   \-                       \-     \-    \-
  Pooled                     2966   138   96.6 (84.7 to 99.5)      2712         92   97.8 (62.9 to 99.9)      547    16    Not estimable

Ig=immunoglobulin; TP=true positive; FN-false negative; TN=true negative; FP=false positive; ELISA=enzyme linked immunosorbent assay; LFIA=lateral flow immunoassay; CLIA=chemiluminescent immunoassay.

Pooled estimates were calculated using bivariate random effects meta-analysis; as such, they depart from what would be estimated by simple division of numerator by denominator. Supplementary table S4 lists the names of commercial assays.

Supplementary table S5 provides sensitivity and specificity reported in three studies that used serological test methods other than ELISAs, LFIAs, or CLIAs. Sensitivity or specificity, or both were low for all, with the exception of an IgM enzyme immunoassay in one arm of 16 patients. Supplementary table S6 reports sensitivity and specificity of serological tests that measured IgA (one ELISA, one CLIA)[@ref47] [@ref51] and those measuring total immunoglobulin levels (three ELISAs, one CLIA, one LFIA).[@ref20] [@ref30] [@ref51] All four studies were classified as high risk of bias from patient selection, and unclear risk of bias from performance of the reference standard, and three had high or unclear risk of bias in the domains of index test performance and flow and timing (supplementary figure S1). Sensitivity ranged from 93.1% to 98.6%, and specificity from 93.3% to 100%.

[Table 5](#tbl5){ref-type="table"} reports stratified meta-analyses for evaluating potential sources of heterogeneity in sensitivity and specificity. Peer review was not associated with accuracy. For ELISAs and LFIAs, accuracy estimates at the sample level (ie, in studies when it was possible for patients to contribute more than one sample to the analysis) were similar to estimates using only one sample for each patient. For CLIAs, specificity was higher from studies reported at the sample level. Point estimates for pooled sensitivity and specificity were higher when both surface and nucleocapsid proteins were used, although confidence intervals overlapped. Point estimates of pooled sensitivity were lower for commercial kits versus in-house assays, for all three methods, with the strongest difference seen for LFIAs, where the sensitivity of commercial kits was 65.0% (49.0% to 78.2%) and that of non-commercial tests was 88.2% (83.6% to 91.3%). For all three test methods, pooled specificity was high when measured in populations where covid-19 was not suspected, regardless of whether the sampling had been done before or during the epidemic. For both LFIAs and CLIAs, pooled specificity was lower among individuals with suspected covid-19 compared with other groups; similar data were not available for ELISAs. For LFIAs, specificity was lower when estimated in individuals with other viral infections, but this was not the case for ELISAs or CLIAs.

###### 

Accuracy of covid-19 serology tests stratified by potential sources of heterogeneity\*†

  Potential source of heterogeneity                                                             No of arms   TP     FN    Pooled sensitivity (95% CI)   TN     FP    Pooled specificity (95% CI)
  --------------------------------------------------------------------------------------------- ------------ ------ ----- ----------------------------- ------ ----- -----------------------------
  Peer reviewed:                                                                                                                                                     
   ELISA: Yes                                                                                   10           772    190   83.7 (74.1 to 92.5)           1916   13    99.3 (98.7 to 99.7)
   ELISA: No                                                                                    8            613    129   85.3 (75.7 to 91.9)           1452   39    98.4 (94.6 to 99.7)
   LFIA: Yes                                                                                    7            446    106   72.4 (37.9 to 93.6)           439    18    96.4 (88.3 to 99.3)
   LFIA: No                                                                                     32           1566   767   70.3 (52.1 to 83.7)           2935   160   97.3 (94.9 to 98.6)
   CLIA: Yes                                                                                    8            249    53    89.7 (61.3 to 98.7)           769    105   86.5 (80.3 to 99.4)
   CLIA: No                                                                                     9            1970   373   90.5 (73.2 to 97.4)           4385   86    99.1 (91.8 to 100)
  Data level:                                                                                                                                                         
   ELISA: Patient                                                                               8            589    133   88.2 (67.1 to 96.9)           1723   18    98.8 (97.0. 99.5)
   ELISA: Sample                                                                                11           796    186   82.2 (76.4 to 87.1)           1655   34    99.8 (97.8 to 100)
   LFIA: Patient                                                                                15           675    211   70.7 (46.9 to 86.1)           799    43    97.2 (92.8 to 99.4)
   LFIA: Sample                                                                                 24           1337   662   75.1 (56.3 to 95.0)           2575   135   97.6 (97.6 to 99.4)
   CLIA: Patient                                                                                11           1490   185   90.7 (80.3 to 96.8)           3915   185   88.4 (48.8. 98.4)
   CLIA: Sample                                                                                 6            729    241   89.3 (45.8 to 96.1)           1239   6     99.8 (98.4 to 100)
  **Antigen target**                                                                                                                                                 
  ELISA:                                                                                                                                                              
   Surface protein                                                                              8            573    166   80.8 (68.1 to 89.9)           1600   35    98.3 (94.9 99.6)
   Nucleocapsid protein                                                                         5            389    108   78.3 (72.5 to 83.2)           670    15    98.2 (92.1 to 99.8)
   Surface and nucleocapsid proteins                                                            5            423    45    92.5 (80.4 to 98.1)           1098   2     99.9 (99.8 to 100)
  LFIA:                                                                                                                                                               
   Surface protein                                                                              6            594    191   67.4 (35.7 to 89.4)           439    51    92.6 (82.6 to 98.7)
   Nucleocapsid protein                                                                         1            26     29    \-                            45     0     \-
   Surface and nucleocapsid proteins                                                            7            363    119   78.9 (64.4 to 91)             967    20    98.7 (91.9 to 100)
  CLIA:                                                                                                                                                               
   Surface protein                                                                              1            355    197   \-                            334    0     \-
   Nucleocapsid protein                                                                         1            72     7     \-                            64     16    \-
   Surface and nucleocapsid proteins                                                            10           1420   152   91.6 (72.7 to 98.2)           4601   92    98.4 (94.8 to 99.7)
  Commercial kit:                                                                                                                                                     
   ELISA: Yes                                                                                   10           937    228   80.9 (73.9 to 86.5)           1357   35    98.7 (94.4 to 99.8)
   ELISA: No                                                                                    18           448    91    87.3 (72.4 to 95.3)           2011   17    99.3 (98.1 to 99.8)
   LFIA: Yes                                                                                    36           1547   812   65.0 (49.0 to 78.2)           3206   165   97.0 (94.8 to 98.5)
   LFIA: No                                                                                     3            465    61    88.2 (83.6 to 91.3)           168    13    94.9 (79.1 to 99.8)
   CLIA: Yes                                                                                    7            227    61    84.2 (61.4 to 96.3)           491    83    90.8 (19.8 to 99.7)
   CLIA: No                                                                                     8            1651   296   93.9 (75.6 to 98.9)           4515   99    99.2 (87.0 to 100)
  **Population for estimating specificity†**                                                                                                                         
  ELISA:                                                                                                                                                              
   Samples collected before covid-19 epidemic                                                   7                                                       1360   30    98.7 (93.4 to 99.9)
   Samples collected during covid-19 epidemic in individuals not suspected of having covid-19   10           \-     \-                                  1441   9     99.5 (97.9 to 100)
   Individuals with suspected covid-19 but RT-PCR negative result                               \-           \-     \-    \-                            \-     \-    \-
   Individuals with confirmed other viral infection                                             5            \-     \-                                  425    21    96.3 (62.2 to 100)
  LFIA:                                                                                                                                                               
   Samples collected before covid-19 epidemic                                                   25                                                      2071   79    98.2 (96.1 to 99.7)
   Samples collected during covid-19 epidemic in individuals not suspected of having covid-19   7            \-     \-    \-                            518    5     99.0 (97.8 to 100)
   Individuals with suspected covid-19 but RT-PCR negative result                               7            \-     \-    \-                            424    43    90.7 (87.5 to 93.2)
   Individuals with confirmed other viral infection                                             12                                                      445    56    90.8 (76.2 to 95.7)
  CLIA                                                                                                                                                                
   Samples collected before covid-19 epidemic                                                   1            \-     \-    \-                            642    18    \-
   Samples collected during covid-19 epidemic in individuals not suspected of having covid-19   7                         \-                            4167   125   97.8 (86.7 to100)
   Individuals with suspected covid-19 but RT-PCR negative result                               8            \-     \-                                  242    92    77.1 (15.6 to 98.4)
   Individuals with confirmed other viral infection                                             1            \-     \-    \-                            334    0     \-

TP=true positive; FN=false negative; TN=true negative; FP=false positive; ELISA=enzyme linked immunosorbent assay; LFIA=lateral flow immunoassay; CLIA=chemiluminescent immunoassay; RT-PCR=reverse transcriptase polymerase chain reaction

Pooled estimates were calculated using bivariate random effects meta-analysis; as such, they depart from what would be estimated by simple division of numerator by denominator. Supplementary table S4 lists the names of commercial assays.

Pooled estimates were calculated using univariate random effects meta-analysis.

[Table 6](#tbl6){ref-type="table"} shows pooled sensitivity stratified by the timing of sample collection in relation to symptom onset. Regardless of immunoglobulin class or test method, pooled sensitivity was lowest in the first week of symptom onset and highest in the third week or later. Data on specificity stratified by timing were not available.

###### 

Sensitivity by serology test method and timing in relation to onset of symptoms\*†

  Time post-onset        IgM         IgG                                             
  ---------------------- ----- ----- ----- --------------------- -- ---- ----- ----- ---------------------
  ELISA:                                                                              
   First week            4     36    99    26.7 (15.6 to 35.6)      5    39    133   23.7 (12.7 to 38.1)
   Second week           5     169   80    57.6 (15.9 to 88.2)      6    165   91    65.3 (46.3 to 79.4)
   Third week or later   5     146   32    78.4 (54.1 to 91.9)      6    165   36    82.1 (76.4 to 89.0)
  LFIA:                                                                               
   First week            15    105   301   25.3 (16.3 to 31.1)      15   74    329   13.4 (4.7 to 29.6)
   Second week           15    471   265   51.8 (30.3 to 69.6)      15   442   312   50.1 (24.8 to 77.0)
   Third week or later   15    304   152   69.9 (58.4 to 79.9)      15   361   95    79.7 (71.4 to 86.9)
  CLIA:                                                                               
   First week            5     28    19    50.3 (10.9 to 81.2)      5    25    22    53.2 (28.7 to 67.6)
   Second week           4     70    33    74.3 (16.1 to 99.4)      4    82    18    85.4 (48.1 to 98.1)
   Third week or later   5     280   44    90.6 (51.8 to 99.4)      5    321   7     98.9 (86.9 to 100)

Ig=immunoglobulin; TP=true positive; FN=false negative; ELISA=enzyme linked immunosorbent assay; LFIA=lateral flow immunoassay; CLIA=chemiluminescent immunoassay.

First week range: 0-7 days (one cohort reporting 0-10 days is counted here), second week: 7-14 days, third week: 15 days or more.

Pooled estimates were calculated using univariate random effects meta-analysis, which is why they depart from estimates calculated by simple division of true positives by the sum of true positives and false negatives.

[Table 7](#tbl7){ref-type="table"} provides a summary of our main findings, with examples of hypothetical testing outcomes for 1000 people undergoing serological testing in settings with a prevalence of SARS-CoV-2 ranging from 5%, 10%, and 20%. For example, in a population with a true SARS-CoV-2 prevalence of 10%, for every 1000 people tested with an LFIA: among those who had covid-19, 66 will test positive and 34 will be incorrectly classified as uninfected. Among those without covid-19, 869 will test negative and 31 will be incorrectly classified as having antibodies to SARS-CoV-2.

###### 

Summary of main findings

  Test method                                                                   Classification by serology test      Results per 1000 patients tested (95% CI)                      
  ----------------------------------------------------------------------------- ------------------------------------ ------------------------------------------- ------------------ ------------------
  **Population: SARS-CoV-2 infected**                                                                                                                                               
  ELISA (IgG or IgM):                                                                                                                                                                
   9 studies, 766 samples. Pooled sensitivity 84.3% (95% CI 75.6% to 90.9%)     Correctly classified as infected     42 (38 to 45)                               84 (76 to 91)      169 (151 to 182)
  Incorrectly classified as uninfected                                          8 (5 to 12)                          16 (9 to 24)                                31 (18 to 49)      
  LFIA (IgG or IgM):                                                                                                                                                                 
   11 studies, 2660 samples. Pooled sensitivity 66.0% (95% CI 49.3% to 79.3%)   Correctly classified as infected     33 (25 to 40)                               66 (49 to 79)      132 (99 to 159)
  Incorrectly classified as uninfected                                          17 (10 to 25)                        34 (21 to 51)                               68 (41 to 101)     
  CLIA (IgG or IgM):                                                                                                                                                                 
   2 studies, 375 samples. Pooled sensitivity 97.8% (95% CI 46.2% to 100%)      Correctly classified as infected     49 (23 to 50)                               98 (46 to 100)     196 (92 to 200)
  Incorrectly classified as uninfected                                          1 (0 to 27)                          2 (0 to 54)                                 4 (0 to 108)       
  **Population: not infected with SARS-CoV-2**                                                                                                                                      
  ELISA (IgG or IgM):                                                                                                                                                                
   6 studies, 1109 samples. Pooled specificity 97.6% (95% CI 93.2% to 99.4%)    Correctly classified as uninfected   931 (884 to 941)                            882 (837 to 891)   784 (744 to 792)
  Incorrectly classified as infected                                            19 (9 to 66)                         18 (9 to 63)                                16 (8 to 56)       
  LFIA (IgG or IgM):                                                                                                                                                                 
   11 studies, 2874 samples. Pooled specificity 96.6% (95% CI 94.3% to 98.2%)   Correctly classified as uninfected   918 (896 to 933)                            869 (849 to 884)   773 (754 to 786)
  Incorrectly classified as infected                                            32 (17 to 54)                        31 (16 to 51)                               27 (14 to 46)      
  CLIA (IgG):                                                                                                                                                                        
   9 studies, 2804 samples. Pooled specificity 97.8% (95% CI 62.9% to 99.9%)    Correctly classified as uninfected   929 (598 to 949)                            880 (566 to 899)   782 (503 to 799)
  Incorrectly classified as infected                                            21 (1 to 352)                        20 (1 to 334)                               18 (1 to 297)      

Quality of evidence and practical implications: Pooled sensitivity and specificity should be interpreted with caution. Accuracy might have been over-estimated in most studies owing to bias arising from patient selection or how index and reference tests were performed, or both. Estimates of sensitivity and specificity were inconsistent between studies (heterogeneity was important). Estimates might have limited applicability to outpatient settings and for testing at the point of care. Point-of-care LFIAs consistently had the lowest sensitivity and specificity. The poorest performance was seen with commercial LFIA kits; these tests should not be used for clinical purposes. Clinical studies designed to overcome the weaknesses are urgently needed.

RT-PCR=reverse transcriptase polymerase chain reaction; ELISA=enzyme linked immunosorbent assay; LFIA=lateral flow immunoassay; CLIA=chemiluminescent immunoassay; Ig=immunoglobulin; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2; covid-19=coronavirus disease 2019.

Index test: serology tests to detect immunoglobulins to SARS-CoV-2. Target condition: covid-19, reference standard: RT-PCR, Studies: predominantly case-control design diagnostic test accuracy.

Discussion
==========

In this systematic review and meta-analysis, existing evidence on the diagnostic accuracy of serological tests for covid-19 was found to be characterised by high risks of bias, heterogeneity, and limited generalisability to point-of-care testing and to outpatient populations. We found sensitivities were consistently lower with the LFIA method compared with ELISA and CLIA methods. For each test method, the type of immunoglobulin being measured---IgM, IgG, or both---was not associated with diagnostic accuracy. Pooled sensitivities were lower with commercial kits and in the first and second week after symptom onset compared with the third week or later. Pooled specificities of each test method were high. However, stratified results suggested specificity was lower in individuals with suspected covid-19, and that other viral infections could lead to false positive results for the LFIA method. These observations indicate important weaknesses in the evidence on covid-19 serological tests, particularly those being marketed as point-of-care tests.

Meaning of the study
--------------------

The utility of a low cost, rapid, and accurate point-of-care test[@ref55] has spurred the development and marketing of several covid-19 LFIA serological tests.[@ref56] We found only two studies where LFIA had been performed at the point of care. The low sensitivity of LFIA is of particular concern given that most studies used sample preparation steps that are likely to increase sensitivity compared with the use of whole blood as would be done at the point of care. These observations argue against the use of LFIA serological tests for covid-19 beyond research and evaluation purposes and support interim recommendations issued by the World Health Organization.[@ref57]

Cautious interpretation of specificity estimates is warranted for several reasons. Importantly, few data were available from people who were tested because of suspected SARS-CoV-2 infection; hence our overall pooled estimates might not be generalisable to people who need testing because of covid-19 symptoms. For CLIAs, the lower specificity among people with suspected covid-19 could be a spurious finding from a false negative RT-PCR result, given that the specificity for CLIAs was high among people with confirmed other viral infections. By contrast, for LFIAs, other viral infections could have contributed to the lower specificity in suspected covid-19.

Our time stratified analyses suggest that current serological tests for covid-19 have limited utility in the diagnosis of acute covid-19. For example, of those tested for covid-19 within one week of symptom onset, on average 44% to 87% will be falsely identified as not having infection. And while sensitivity estimates were higher in the third week or later, even at this time point we found important false negative rates. For example, in people with covid-19 who are tested three weeks after symptom onset, ELISA IgG will misclassify 18% as not having been infected and LFIA IgG will misclassify 30%.

Overall, the poor performance of existing serological tests for covid-19 raises questions about the utility of using such methods for medical decision making, particularly given time and effort required to do these tests and the challenging workloads many clinics are facing. Our findings should also give pause to governments that are contemplating the use of serological tests---in particular, point-of-care tests---to issue immunity "certificates" or "passports." For example, if an LFIA is applied to a population with a true SARS-CoV-2 prevalence of 10%, for every 1000 people tested, 31 who never had covid-19 will be incorrectly told they are immune, and 34 people who had covid-19 will be incorrectly told that they were never infected.

Strengths and limitations of this review
----------------------------------------

Our review has several strengths. We used sensitive search strategies and included pre-peer reviewed literature, and although our use of studies published as preprints might be criticised, we found that the peer reviewed literature also had biases. Moreover, preprints have taken an unprecedented larger role[@ref58] in discussions and policy making around covid-19---hence the importance of subjecting pre-peer reviewed literature to critical appraisal. Another strength of our review was that two independent reviewers systematically assessed potential sources of bias. Finally, a second investigator verified all data extraction.

Our study also has some limitations. Most importantly, we compared pooled estimates between different study populations. As such, the possibility of confounding exists (eg, from differences in timing of sampling between studies), explaining differences in sensitivity or specificity.[@ref59] This approach was taken because few studies performed head-to-head comparisons. We did not perform metaregression as many studies would have been excluded owing to limited reporting of covariates. Another limitation is that as we did not search Embase we might have missed some published studies.

Conclusion and future research
------------------------------

Future studies to evaluate serological tests for covid-19 should be designed to overcome the major limitations of the existing evidence base. This can be readily accomplished by adhering to the fundamentals of the design for diagnostic accuracy studies: a well defined use-case (ie, specific purpose for which the test is being used); consecutive sampling of the target population within the target use-case; performance of the index test in a standardised and blinded manner using the same methods that will be applied in the specialty; and ensuring the reference test is accurate, performed on all participants, and interpreted blind to the results of the index test. To reduce the likelihood of misclassification, the reference standard should consist of RT-PCR performed on at least two consecutive specimens, and, when feasible, include viral cultures. To reduce variability in estimates and enhance generalisability, sensitivity and specificity should be stratified by setting (outpatient versus in-patient), severity of illness, and the number of days elapsed since symptom onset.

In summary, we have found major weaknesses in the evidence base for serological tests for covid-19. The evidence does not support the continued use of existing point-of-care serological tests for covid-19. While the scientific community should be lauded for the pace at which novel serological tests have been developed, this review underscores the need for high quality clinical studies to evaluate these tools. With international collaboration, such studies could be rapidly conducted and provide less biased, more precise, and more generalisable information on which to base clinical and public health policy to alleviate the unprecedented global health emergency that is covid-19.

### What is already known on this topic

1.  Serological tests to detect antibodies against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) could improve diagnosis of coronavirus disease 2019 (covid-19) and be useful tools for epidemiological surveillance

2.  The number of serological tests has rapidly increased, and many are being marketed for point-of-care use

3.  The evidence base supporting the diagnostic accuracy of these tests, however, has not been formally evaluated

### What this study adds

1.  The available evidence on the accuracy of serological tests for covid-19 is characterised by risks of bias and heterogeneity, and as such, estimates of sensitivity and specificity are unreliable and have limited generalisability

2.  Evidence is particularly weak for point-of-care serological tests

3.  Caution is warranted if using serological tests for covid-19 for clinical decision making or epidemiological surveillance

4.  Current evidence does not support the continued use of existing point-of-care tests
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